Growth Metrics

Vertex Pharmaceuticals (VRTX) Non-Current Deferred Tax Liability (2016 - 2018)

Vertex Pharmaceuticals (VRTX) has 10 years of Non-Current Deferred Tax Liability data on record, last reported at $9.4 million in Q3 2018.

  • For Q3 2018, Non-Current Deferred Tax Liability fell 11.87% year-over-year to $9.4 million; the TTM value through Sep 2018 reached $9.4 million, down 11.87%, while the annual FY2017 figure was $5.5 million, 95.88% down from the prior year.
  • Non-Current Deferred Tax Liability reached $9.4 million in Q3 2018 per VRTX's latest filing, down from $9.6 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $136.6 million in Q2 2017 and bottomed at $5.5 million in Q4 2017.
  • Average Non-Current Deferred Tax Liability over 5 years is $79.1 million, with a median of $112.3 million recorded in 2016.
  • Peak YoY movement for Non-Current Deferred Tax Liability: skyrocketed 643.78% in 2016, then plummeted 95.88% in 2017.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $15.0 million in 2014, then skyrocketed by 634.11% to $110.4 million in 2015, then rose by 21.39% to $134.1 million in 2016, then tumbled by 95.88% to $5.5 million in 2017, then soared by 70.61% to $9.4 million in 2018.
  • Per Business Quant database, its latest 3 readings for Non-Current Deferred Tax Liability were $9.4 million in Q3 2018, $9.6 million in Q1 2018, and $5.5 million in Q4 2017.